

Technology Appraisal Committee D Interests Register

Atezolizumab monotherapy for untreated PD-L1 positive metastatic non-small-cell lung cancer [ID1678]

Publication Date: 02/06/2021

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Professor David Meads	Clinical expert	Non-financial	University of Leeds has received funding from Roche, Celgene, and Sanofi for research in an unrelated area.	15/02/2021	11/03/2021	N/A	It was agreed that this declaration would not prevent Professor Meads from participating in discussions on this appraisal.
Dr Yvonne Summers	Clinical expert	Financial	Dr Summers has participated in advisory boards for NSCLC with; Roche, Takeda, Pfizer, AstraZeneca, BMS, Lily & Amgen.	30/04/2020	11/03/2021	N/A	It was agreed that this declaration would not prevent Dr Summers from providing expert advice to the committee.